Sensyne Health has announced the appointment of Dr Ian Hudson to the Board as it independent non-executive director.
Effective from June 28, Hudson will lead the Oxford-based clinical Artificial Intelligence (AI) company as a non-executive director, Sensyne said on Friday (June 18).
Hudson has extensive knowledge of the healthcare and pharmaceutical sector, having served as chief executive of the Medicines and Healthcare Products Regulatory Agency (MHRA) from 2013 to 2019.
Prior to joining the MHRA, Hudson held various senior roles at GSK when it was known as SmithKline Beecham, working for more than a decade in clinical research and development.
He is currently serving as senior advisor, Integrated Development for the Bill and Melinda Gates Foundation.
Hudson’s working areas include optimising clinical studies and strengthening regulatory systems in low-resource regions, as well as providing regulatory input to teams working on malaria, polio, and Covid-19 drugs.
